Medtronic, Boston Scientific ink patent accord
This article was originally published in The Gray Sheet
Executive Summary
Firms settle two patent suits and agree to stand down in three others, ending all current litigation between the companies related to interventional cardiology and endovascular repair technology intellectual property, the companies announce Jan. 27. The two settled cases and one of the discontinued cases were pending in the U.S. District Court for the Eastern District of Texas. The other two discontinued cases were filed in the U.S. District Court for the Northern District of California. While terms of the settlement were not disclosed, Boston Scientfic notes that the agreement will have no material impact on its financial results
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.